Therapy Detail

Therapy Name Ramucirumab + Docetaxel
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Docetaxel Taxotere Docetaxel anhydrous|Docefrez Antimicrotubule Agent 11 Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (NCI Drug Dictionary).
Ramucirumab Cyramza LY3009806 VEGFR2 Antibody 4 Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (NCI Drug Dictionary). Cyramza (ramucirumab) is approved for gastric and gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and colorectal cancer (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 negative Her2-receptor negative breast cancer no benefit Ramucirumab + Docetaxel Phase III Actionable In a Phase III trial, Cyramze (ramucirumab) in combination with Taxotere (docetaxel) did not improve clinical outcomes in ERBB2 (HER2)-negative breast cancer patients (PMID: 25185099). 25185099
Unknown unknown non-small cell lung carcinoma not applicable Ramucirumab + Docetaxel FDA approved Actionable In a Phase III trial that supported FDA approval, treatment with a combination of Cyramza (ramucirumab) and Taxotere (docetaxel) resulted in improved overall survival compared to treatment with Taxotere (docetaxel) and a placebo in patients with metastatic non-small cell lung cancer (PMID: 24933332). detail... 24933332
Unknown unknown transitional cell carcinoma not applicable Ramucirumab + Docetaxel Phase III Actionable In a Phase III trial, Cyramza (ramucirumab) and Taxotere (docetaxel) combination treatment resulted in improved median progression-free survival (4.1 vs 2.8 months) and objective response rate (24.5% vs 14.0%) when compared to Taxotere (docetaxel) single treatment in urothelial carcinoma patients (Annals of Oncology (2017) 28 (suppl_5): v605-v649; NCT02426125). detail...
Unknown unknown transitional cell carcinoma not applicable Ramucirumab + Docetaxel Phase II Actionable In a Phase II trial, Cyramza (ramucirumab) and Taxotere (docetaxel) combination treatment resulted in improved median progression-free survival (5.4 months) when compared to Taxotere (docetaxel) single treatment (2.8 months) in urothelial carcinoma patients (PMID: 26926681). 26926681
Clinical Trial Phase Therapies Title Recruitment Status
NCT02831491 Phase II Ramucirumab + Docetaxel A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer Withdrawn